Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy

Early relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an often unsuccessful therapeutic challenge. Since treatment options are few and efficacy is low, new approaches such as de novo allo-HSCT, targeted therapies and biomodulatory drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattner, Anna-Sophia, Holler, Ernst, Herr, Wolfgang, Reichle, Albrecht, Wolff, Daniel, Heudobler, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190808/
https://www.ncbi.nlm.nih.gov/pubmed/32391254
http://dx.doi.org/10.3389/fonc.2020.00443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190808/
https://www.ncbi.nlm.nih.gov/pubmed/32391254
http://dx.doi.org/10.3389/fonc.2020.00443

Ejemplares similares